Literature DB >> 26099985

Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?

Axel Hauschild1, Claus Garbe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26099985     DOI： 10.1038/nrclinonc.2015.118

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

Authors:  Paul B Chapman; Sandra P D'Angelo; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

7.  Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Authors:  Rituparna Das; Rakesh Verma; Mario Sznol; Chandra Sekhar Boddupalli; Scott N Gettinger; Harriet Kluger; Margaret Callahan; Jedd D Wolchok; Ruth Halaban; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

8.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 9.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

10.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
  10 in total
  6 in total

1.  STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.

Authors:  David G Leach; Neeraja Dharmaraj; Stacey L Piotrowski; Tania L Lopez-Silva; Yu L Lei; Andrew G Sikora; Simon Young; Jeffrey D Hartgerink
Journal:  Biomaterials       Date:  2018-02-06       Impact factor: 12.479

2.  Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

Authors:  Elizabeth Ann L Enninga; Justin C Moser; Amy L Weaver; Svetomir N Markovic; Jerry D Brewer; Alexey A Leontovich; Tina J Hieken; Lynne Shuster; Lisa A Kottschade; Ariadna Olariu; Aaron S Mansfield; Roxana S Dronca
Journal:  Cancer Med       Date:  2017-09-06       Impact factor: 4.452

3.  Macrophage Membrane-Camouflaged shRNA and Doxorubicin: A pH-Dependent Release System for Melanoma Chemo-Immunotherapy.

Authors:  Chengli Yang; Yang Ming; Kai Zhou; Ying Hao; Danrong Hu; Bingyang Chu; Xinlong He; Yun Yang; Zhiyong Qian
Journal:  Research (Wash D C)       Date:  2022-02-08

4.  Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Authors:  Kristen M Beck; Joanna Dong; Larisa J Geskin; Vincent P Beltrani; Richard G Phelps; Richard D Carvajal; Gary Schwartz; Yvonne M Saenger; Robyn D Gartrell
Journal:  J Immunother Cancer       Date:  2016-04-19       Impact factor: 13.751

5.  DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment.

Authors:  Qiang Lv; Chaoliang He; Fenli Quan; Shuangjiang Yu; Xuesi Chen
Journal:  Bioact Mater       Date:  2017-09-06

6.  Attachable Hydrogel Containing Indocyanine Green for Selective Photothermal Therapy against Melanoma.

Authors:  Juyoung Hwang; Jun-O Jin
Journal:  Biomolecules       Date:  2020-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.